Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation
Issued Date
2024-03-01
Resource Type
ISSN
22338276
eISSN
22338268
Scopus ID
2-s2.0-85188048457
Journal Title
Asia Pacific Allergy
Volume
14
Issue
1
Start Page
32
End Page
38
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asia Pacific Allergy Vol.14 No.1 (2024) , 32-38
Suggested Citation
Kim C.K., Callaway Z., Park J.S., Pawankar R., Fujisawa T. Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation. Asia Pacific Allergy Vol.14 No.1 (2024) , 32-38. 38. doi:10.5415/apallergy.0000000000000129 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97754
Title
Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation
Author(s)
Corresponding Author(s)
Other Contributor(s)
Abstract
Asthma and allergic rhinitis (AR) are 2 of the most common chronic inflammatory disorders and they appear to be on the rise. Current pharmacotherapy effectively controls symptoms but does not alter the underlying pathophysiology. Allergen immunotherapy (AIT) is an evidence-based therapy for asthma and AR and has been recognized as the only therapeutic method that actually modifies the allergic disease process. There is a lack of objective markers that accurately and reliably reflect the therapeutic benefits of AIT. A biomarker indicating patients that would benefit most from AIT would be invaluable. Eosinophilic inflammation is a cardinal feature of many allergic diseases. Biomarkers that accurately reflect this inflammation are needed to better diagnose, treat, and monitor patients with allergic disorders. This review examines the current literature regarding AIT’s effects on eosinophilic inflammation and biomarkers that may be used to determine the extent of these effects.